Myeloid-Derived Suppressor Cells: Immune-Suppressive Cells That Impair Antitumor Immunity and Are Sculpted by Their Environment
Open accessThe DOI matches its Crossref record; 134 of the 135 references it cites were found in a registry or an index.
Abstract
Myeloid-derived suppressor cells (MDSC) are a diverse population of immature myeloid cells that have potent immune-suppressive activity. Studies in both mice and humans have demonstrated that MDSC accumulate in most individuals with cancer, where they promote tumor progression, inhibit antitumor immunity, and are an obstacle to many cancer immunotherapies. As a result, there has been intense interest in understanding the mechanisms and in situ conditions that regulate and sustain MDSC, and the mechanisms MDSC use to promote tumor progression. This article reviews the characterization of MDSC and how they are distinguished from neutrophils, describes the suppressive mechanisms used by MDSC to mediate their effects, and explains the role of proinflammatory mediators and the tumor microenvironment in driving MDSC accumulation, suppressive potency, and survival.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In preclinical models, both of these innate immune cell types aid tumor growth and metastasis through their secretion of factors that suppress antitumor immune responses, especially those of CD8 + T cells and NK cells (166, 167).”
From Immune Checkpoint Inhibitors for the Treatment of Cancer: Clinical Impact and Mechanisms of Response and Resistance (2021) · cites this paper as [166]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Myeloid-derived-suppressor cells as regulators of the immune system
Gabrilovich, D. I., & Nagaraj, S. (2009) · Nature Reviews Immunology · doi:10.1038/nri2506 · Cited by 6,753 · cited 13×
“In contrast to STAT3, which promotes MDSC accumulation, IRF8 deters PMN-MDSC accumulation.”
BackgroundInfluentialCoordinated regulation of myeloid cells by tumours
Gabrilovich, D. I., Ostrand-Rosenberg, S., & Bronte, V. (2012) · Nature Reviews Immunology · doi:10.1038/nri3175 · Cited by 3,544
Self-citationPolarization of Tumor-Associated Neutrophil Phenotype by TGF-β: “N1” versus “N2” TAN
Fridlender, Z. G., Sun, J., Kim, S., Kapoor, V., Cheng, G., Ling, L., Worthen, G. S., & Albelda, S. M. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.06.017 · Cited by 3,371
Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards
Bronte, V., Brandau, S., Chen, S.-H., Colombo, M. P., Frey, A. B., Greten, T. F., Mandruzzato, S., Murray, P. J., Ochoa, A., Ostrand-Rosenberg, S., et al. (2016) · Nature Communications · doi:10.1038/ncomms12150 · Cited by 2,751 · cited 1×
“Because there has been considerable discussion about the nomenclature, phenotype, and function of this cell population, an international group of investigators in the field recently recommended nomenclature and characterization standards for MDSC (15).”
BackgroundSelf-citationThe Nature of Myeloid-Derived Suppressor Cells in the Tumor Microenvironment
Kumar, V., Patel, S., Tcyganov, E., & Gabrilovich, D. I. (2016) · Trends in Immunology · doi:10.1016/j.it.2016.01.004 · Cited by 2,008
Gabrilovich, D. I., Chen, H. L., Girgis, K. R., Cunningham, H. T., Meny, G. M., Nadaf, S., Kavanaugh, D., & Carbone, D. P. (1996) · Nature Medicine · doi:10.1038/nm1096-1096 · Cited by 1,977
Regulation of immune responses by L-arginine metabolism
Bronte, V., & Zanovello, P. (2005) · Nature Reviews Immunology · doi:10.1038/nri1668 · Cited by 1,775
Myeloid-Derived Suppressor Cells: Linking Inflammation and Cancer
Ostrand-Rosenberg, S., & Sinha, P. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0802740 · Cited by 1,736 · cited 1×
“driving force for MDSC, and the hypothesis that one of the mechanisms by which inflammation drives cancer risk and tumor progression is through the suppression of antitumor immunity (47).”
Self-citationHuang, B., Pan, P.-Y., Li, Q., Sato, A. I., Levy, D. E., Bromberg, J., Divino, C. M., & Chen, S.-H. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-1299 · Cited by 1,435
Almand, B., Clark, J. I., Nikitina, E., van Beynen, J., English, N. R., Knight, S. C., Carbone, D. P., & Gabrilovich, D. I. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.166.1.678 · Cited by 1,337
Research works printed but not linked: 1
- Geis-Asteggiante L 2017 Quantitative analysis of intact proteins and RNAs carried by immunosuppressive exosomes Ph.D. thesis University of Maryland
Cited by
Items 501–523 of 523
Rôle des neutrophiles dans la carcinogenèse et l’adénocarcinome colorectal
Sarabi, M. (2022) · theses.fr (ABES) · doi:10.70675/6d957df5z44a5z4e00z8ab8z3f0fe13e1884
Dual Immune-Regulatory Role of DAMPs in Glioblastoma Radiotherapy
Rawojć, K., Jezierska, K., & Kisielewicz, K. (2026) · Journal of Nanotheranostics · doi:10.3390/jnt7020008
“Serial sampling studies demonstrate that radiation-induced DAMP release is dynamic over the course of therapy and can be detected using liquid biopsy approaches, including plasma and cerebrospinal fluid analyses, as demonstrated in clinical observations by Clasen et al. [10].”
InfluentialDai, W., Li, Q., Wang, M., Wang, C., & Cao, H. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1844002
Myeloid-Derived Suppressor Cells in Inflammatory Arthritis
McDougle, D. R., Moon, J. J., & Fox, D. A. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27125365
“MDSCs suppress both innate and adaptive immunity through complex, interdependent mechanisms, including metabolic/enzymatic pathways (e.g., arginase-1, iNOS), cytokine and chemokine signaling (e.g., IL-10, TGF-β ), and cell–cell interactions (e.g., PD-L1) [3,5].”
Dynamic myeloid suppressor states in cancer and inflammation and their therapeutic potential
Pommier, A., & Cancelas, J. A. (2026) · Current Opinion in Hematology · doi:10.1097/moh.0000000000000939 · Cited by 1
Erdal, G. Ş., Işıksaçan, N., Gümüşoğlu, A. Y., Kabuli, H. A., Yildiz, T., Taşçı, T. S., Tural, D., Tas, S. K., & Atar, P. (2026) · The Tohoku Journal of Experimental Medicine · doi:10.1620/tjem.2026.j017
Kuznetsova, A. D., Managarova, A. E., Kurbanova, Z. M., Mogilina, D. A., Astakhova, I. Y., Girya, A. I., Albotova, A. D., Esaulova, E. I., Bukhtoyarova, Y. A., Budunova, A. A., et al. (2026) · V F Snegirev Archives of Obstetrics and Gynecology · doi:10.17816/aog697267
Sex-Biased Immunity: The Hidden Variable in Immuno-oncology
Brown, K., Hornick, N. I., & Ruhland, M. K. (2026) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-24-1223
The CD73-adenosine axis in melanoma: from multidimensional regulation to precision immunotherapy
Liu, X., Sun, P., Chen, C., & Chen, X. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1839832
Myeloid-Derived Suppressor Cells (MDSCs) in Cardiovascular Risk of Obesity-Associated Diabetes
Flores-Campos, R., Hontecillas‐Prieto, L., García-Domínguez, D. J., Fernández‐Suárez, A., Egusquiza-Lasuen, I., Pérez, A., Ribalta, J., Pedro‐Botet, J., Sánchez‐Margalet, V., & the Cardiovascular Disease Group of the Spanish Diabetes Society (SED) (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27177872
“In contrast, G-MDSCs primarily rely on the heightened production of intra-cellular reactive oxygen species (ROS), the release of arginase-1 (ARG1)—which depletes local L-arginine supplies to arrest T-cell proliferation—and the production of prostaglandin E2 (PGE 2 ) [10,27–29].”
Ning, F., Montalvan, E. S. A., Meyer, T. J., Kaczanowska, S., Kaplan, R., & Annunziata, C. M. (2026) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2026-014938
Pan, J., Li, B., Lau, L. Y., Hong, Z., & Chen, Y. (2026) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2026.189702
Hu, S., Zhang, X., Ge, C., Zhou, S., Ba, J., Wang, J., Du, J., & Cai, C. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1855615
Temuri, U. H. (2026) · Oncology Reviews · doi:10.3389/or.2026.1953850
“…to reduced production of effector cytokine and exhaustion of T cells (22, 27–29), while the suppression of effector T-cells and antigen presenting cells is carried out by Tregs (68, 69), MDSCs inhibit cell activity (70, 71), and effective T-cell priming may be impaired by tolerogenic DC (65–67).”
InfluentialLi, Y., Guo, Y., Peng, S., Mo, P., Cheng, D., Wang, Y., Yang, Y., Ren, Y., Liang, P., Liang, X., et al. (2026) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2026-014952
Wang, Z. P., Luo, Z., Wang, L., Tang, J., Zhang, Z., & Fan, X. (2026) · Cancer Medicine · doi:10.1002/cam4.72335
ExpertTwins: Auditable Long Horizon Scientific Panels through Grounded ExpertisePreprint
pour, A. F., & Shirinifard, A. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.10.06.757114
Metadata
- Authors
- Ostrand-Rosenberg, S., & Fenselau, C.
- Affiliations
- Department of Biological Sciences, University of Maryland Baltimore County , Baltimore, MD 21250
- University of Maryland, College Park (US)
- Venue
- The Journal of Immunology
- Publisher
- Oxford University Press (OUP)
- Published
- 2018-01
- Volume
- 200
- Issue
- 2
- Pages
- 422-431
- ISSN
- 0022-1767 (ISSN-L)
- 1550-6606
- PMC
- PMC5765878
- OpenAlex
- W2783633531
- Cited by
- 509
- References
- 135
- Citations by year
- 2026: 34 · 2025: 42 · 2024: 44 · 2023: 61 · 2022: 71 · 2021: 117 · 2020: 80 · 2019: 39 · 2018: 21
- FWCI
- 6.57
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- The Journal of Immunology (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Maryland Shared Open Access Repository (USMAI Consortium) (submittedVersion)
- Digital Repository at the University of Maryland (University of Maryland College Park)
- Funders
- National Institutes of Health (1s10od019938-01, RO1 GM021248)
- National Cancer Institute (R01CA084232, R01CA115880)
- National Institute of General Medical Sciences (R01GM021248)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Immune cells in cancer
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Keywords
- myeloid-derived suppressor cells, tumor immunosuppression, antitumor immunity, tumor microenvironment, pro-inflammatory mediators, neutrophils, cancer immunotherapy resistance, tumor progression
- MeSH terms
- Myeloid-Derived Suppressor Cells, Animals, Humans, Neoplasms, Phenotype, Cytokines, Disease Progression, Inflammation Mediators, Immunomodulation, Tumor Microenvironment
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.